key: cord-0870187-igunzvfn
authors: Antony, Suresh J; Davis, Michelle A; Davis, Monique G; Almaghlouth, Nouf K; Guevara, Roberto; Omar, Fahad; Del Rey, Fernando; Hassan, Ali; Arian, Muhammad U; Antony, Nishaal; Prakash, Bharat V
title: Early use of tocilizumab in the prevention of adult respiratory failure in SARS‐CoV‐2 infections and the utilization of interleukin‐6 levels in the management
date: 2020-07-09
journal: J Med Virol
DOI: 10.1002/jmv.26288
sha: 8f93ef30c855a94f65b5d1fd04f0ee59f83e4cdf
doc_id: 870187
cord_uid: igunzvfn

BACKGROUND: Respiratory failure in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection appears related to cytokine release syndrome (CRS) that often results in mechanical ventilation (MV). We investigated the role of tocilizumab (TCZ) on interleukin‐6 (IL‐6) trends and MV in SARS‐CoV‐2 patients. METHODS: In this longitudinal observational study, 112 patients were evaluated from 2/1/2020 ‐ 5/31/2020. TCZ was administered followed by methylprednisolone to patients with > 3L oxygen (O2) requirement and pneumonia severity index (PSI) score ≤ 130 with CT scan changes. IL‐6, C‐reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), D‐dimer, and procalcitonin were monitored on days 0, 3, and 6 of therapy. Statistical analyses were performed with significance ≤ 0.05. RESULTS: 80/112 SARS‐CoV‐2‐positive patients (45 males, 56.96%; 34 females, 43.04%) were included in this study. Seven patients expired (8.75%) and nine patients required MV (11.25%). Median IL‐6 levels pre‐administration of TCZ was 342.50 (78.25 ‐ 666.25) pg/mL compared to post‐administration on day 3 (563; 162 ‐ 783) pg/mL (P < 0.00001). On day 6, the median dropped to 545 (333.50 ‐ 678.50) pg/mL compared to day 3 (P = 0.709). CRP, ferritin, LDH, and D‐dimer levels were reduced following TCZ therapy. CONCLUSIONS: Early use of TCZ may reduce the need for MV and decrease CRP, ferritin, LDH, and D‐dimer levels. The sequential use of methylprednisolone for 72 hours seems to potentiate the effect and prolong the suppression of the cytokine storm. IL‐6 levels may be helpful as a prognostic tool. This article is protected by copyright. All rights reserved.

The major pathological hallmark of SARS-CoV-2 is the activation of a cytokine release syndrome. 1 It has been suggested that this syndrome is the product of excess inflammatory chemokine release, a few of which are IL-6, interleukin-1β (IL-1β), and tumor necrosis factor-alpha (TNF-α). [1] [2] [3] IL-6 is of particular interest as it is the main cytokine responsible for activating CRS and is secreted by stromal and immune cells. 4, 5 High expression of IL-6 resulting in CRS has been observed in all three coronavirus subtypes, SARS-CoV-1, MERS, and now SARS-CoV-2. 5 Thus, IL-6 levels could be useful in predicting the severity of SARS-CoV-2. 2, 6, 7 This is supported by one study, which concluded with statistical significance that SARS-CoV-2 patient mortality was higher with increasing mean IL-6 values. 1 Hence, physicians should monitor IL-6 levels and use it as a prognostic guide for SARS-CoV-2 disease. However, due to its IL-6 inhibition and ability to limit the extent of proinflammatory states, we propose the use of TCZ in an attempt to avoid worsening respiratory failure which may require intubation due to its IL-6 inhibition and potential This article is protected by copyright. All rights reserved.

ability to limit the extent of the pro-inflammatory state. TCZ is a humanized anti-IL-6 receptor monoclonal antibody that is broadly effective in targeting the two types of IL-6 receptors, membrane-bound (mIL-6R) and soluble (sIL-6R), ultimately blocking both the classical and trans-signaling IL-6 pathways. 4 Our study examines the role of IL-6 in evaluating SARS-CoV-2 disease progression and TCZ's efficacy in preventing or reducing the number of patients placed on MV.

PubMed, Google Scholar, and Medline were used for database collection and literature review on SARS-CoV-2 disease, IL-6, and TCZ. SARS-CoV-2-positive patients from four different hospitals in El Paso, Texas were included within this longitudinal observational study from the period of 2/1/2020 to 5/31/2020. One hundred and twelve SARS-CoV-2-positive patients were evaluated in this study. Our inclusion criteria were patients with positive SARS-CoV-2 PCR, >18 years old, O2 supplement of > 3L, PSI score ≤ 130 with CT scan changes. Exclusion criteria were negative SARS-CoV-2 PCR, mechanically ventilated patients, end-stage comorbid conditions such as cardiomyopathy, cardiac arrhythmia, cancer, septic shock, end-stage renal disease (ESRD), O2 supplement of < 3L, PSI score > 130.

TCZ 4 mg/kg/day q12hr was given to patients within the first 24 hours of hospitalization followed by methylprednisolone 60 mg q8hr for 72 hours. No medications were added to the treatment except for methylprednisolone. Demographic data, medical history, and clinical outcomes were collected from all patients included in this study. This article is protected by copyright. All rights reserved.

Labs monitored on days 0, 3, and 6 included IL-6, CRP, ferritin, LDH, D-dimer, procalcitonin, complete blood count (CBC), complete metabolic panel (CMP), and blood and urine cultures if fever occurred. All patients had chest x-rays or computed tomography (CT) scans upon admission and subsequent imaging studies as needed. The duration of hospital stay was monitored for each patient.

Data were retrieved from electronic health records and computed using Excel 365 version. The Excel-computed data were imported into statistical software, Stata/IC 16.0 for data analysis. Descriptive statistics were presented in frequency and percentages.

Shapiro-Wilk normality test for continuous variables showed that the distribution of data was non-normal, therefore, median (IQR) were used as values for the summary statistics.

The Wilcoxon signed-rank test was used for associating differences in median values for selected independent variables before and after TCZ treatment. Fisher's exact test was used for associating categorical variables with values less than 5. An observation is said to be statistically significant if P-value is less than or equal to 0.05 (P ≤ 0.05). The National Heart, Lung and Blood Institute's 8 Study Quality Assessment Tool was used to analyze the validity of the referenced literature case studies in Table 1 . 32.47%), which can be mainly attributed to the fact that the population of El Paso is predominately Hispanic. In assessing the number of patient comorbidities during the initial presentation, those with ≤2 illnesses were 63.89%, and those with 3 or more illnesses were 36.11%, with a median of 2 illnesses (1 -3). The majority of these comorbidities were hypertension (65.28%) and type II diabetes mellitus (51.39%). In addition, the total number of symptoms on admission were ≤2 symptoms (27.78%), and 3 or more clinical symptoms (72.22%), with a median of 3 symptoms (2 -5). Shortness of breath was the most common presenting symptom (86.11%) followed by fever (73.61%) and cough (68.06%), respectively. Bacterial coinfection was noted in 12 patients (15%) and a limited number of patients encountered multi-organ damage (10, 12.50%). Recent travel history was reported in 11 patients (15.71%) and 34 patients had positive contact history (48.43%). Clinical outcomes in terms of mortality and use of MV among SARS-CoV-2 patients treated with TCZ are summarized in Table 3 . Nine patients (11.3%) were placed on MV, of which 7 (8.7%) expired. The duration of hospital stays ranged from five to ten days for all patients.

As acute SARS-CoV-2 results in elevated IL-6 levels, we used TCZ in the treatment of these patients. Therefore, the level of IL-6 was monitored before and after the use of TCZ as shown in Table 4 . The median IL-6 levels before the administration of TCZ on day 0 was 342.50 (78.25 -666.25) pg/mL compared to after administration of TCZ on day 3, 563 (162 -783) pg/mL (P < 0.00001), reflecting a significant increase in the level post-TCZ use. There was a drop in the median to 545 (33.50 -678.50) pg/mL on day 6 after TCZ treatment, which is considered an 18-point reduction from the median of day 3; however, it did not show any statistical significance (either increase or decrease) in comparison to day 3 (P = 0.709). However, in comparing day 0 to day 6, we noted a statistically significant increase post-TCZ (P = 0.006). This elevation can be explained by the ongoing cytokine storm.

Other laboratory findings of SARS-CoV-2 patients treated with TCZ were studied before and after the use of the medication as summarized in Table 5 . CRP levels were above the normal range initially before TCZ treatment in most patients and significantly dropped after TCZ therapy in the following days. The median values of CRP at first reporting following TCZ use on day 3 and sequentially on day 6 were significantly decreased compared with pre-TCZ therapy, which dropped from 11 (6 -18.75 ) mg/L on day 0 to 5 (2 -13) and 2 (1 -4) mg/L on days 3 and 6, respectively (P < 0.00001).

Ferritin and LDH showed no statistically significant reduction between day 0 before TCZ therapy and immediately after TCZ on day 3. However, both showed a statistically significant reduction in their median values on day 6 compared to before the initiation of the medication. D-dimer did not show any statistical significance before and after TCZ therapy, but there was a statistically significant drop in between day 3 and day 6 following initiation of TCZ. On day 6, D-dimer was 1.2 (0.66 -1.84) mcg/mL compared to 1.2 (0.92 -2.05) mcg/mL on day 3 (P = 0.03).

Procalcitonin levels were noted to be within the normal range as expected in most of our study population. This article is protected by copyright. All rights reserved.

In addition, the association of sociodemographic characteristics, medical history, and clinical presentations, with clinical outcomes in terms of mortality and use of MV is illustrated in Table 6 . It is interesting to note that SARS-CoV-2 patients who have had secondary bacterial coinfections showed a statistically significantly higher proportion of deaths than those without coinfections (57.14% vs. 42.86%; P = 0.008). Also, SARS-CoV-2-positive patients who experienced multi-organ damage were more susceptible to higher mortality (85.71% vs. 5.48%; P < 0.0001).

In this study of 80 patients, the population was predominately Hispanic and male with presentations of hypoxemia requiring > 3 L O2 and chest x-rays showing bilateral infiltrates. All patients had evidence of initial elevation of CRP, ferritin, LDH, and Ddimer in keeping with similar findings in published literature. These inflammatory biomarkers all were reduced by day 6 post-TCZ therapy. In contrast, IL-6 levels appeared to be markedly elevated by day 6 of the disease process. However, patients who were given IL-6 inhibitor tended not to progress to MV as 88.75% from our study population did not use MV. This study suggests that TCZ followed by methylprednisolone is useful in the early stages of respiratory distress secondary to SARS-CoV-. Additionally, IL-6 may be a good indicator for management of the cytokine storm. Moreover, we noted that the addition of steroids appeared to help in reducing the progression of the cytokine storm and the short administration course of steroids has minimized the possible side effects of the medication. We were unable to determine if TCZ would be sufficient alone to treat these patients as the steroids could have enhanced the effects of TCZ.

Currently, the only certain mainstay treatment is not well defined and much of the therapy is based on supportive care. 9 Early treatments included steroids, remdesivir, lopinavir/ritonavir, hydroxychloroquine, azithromycin, IL-6 inhibitors (TCZ), ivermectin, or other IL-1 inhibitors. 4, 7, [9] [10] [11] [12] This study focuses on the early use of TCZ, which is a humanized monoclonal antibody that acts by antagonizing both membrane-bound and soluble IL-6 receptors, thus inhibiting subsequent proinflammatory effects.

TCZ currently has been used in the treatment of rheumatoid arthritis and CRS from chimeric antigen receptor T-cell (CAR T) therapy. 3, 9 These studies showed a resolution of severe fevers, resolution of CRP levels, reduction in the oxygen demand, and improvement in the ground glass opacifications seen on CT scans. 9 The recommended dose of TCZ is 4-8 mg/kg or 400 mg IV x1 dose and an optional second dose 12 hours later not to exceed an 800 mg total dose. Caution is also recommended for immunocompromised patients due to a higher susceptibility of bacterial infection, neutropenia, and thrombocytopenia following TCZ therapy. 9, 13 Interestingly, we did not observe any side effects that required stopping TCZ therapy that could be attributed to the short course of the therapy.

In this group of patients, we noticed a few significant findings that were consistent with previous studies including elevated IL-6 levels in acute CRS and elevated CRP, LDH, ferritin, and D-dimer levels. [14] [15] [16] [17] As expected, procalcitonin levels were not markedly elevated except when there appeared to be a secondary bacterial pneumonia.

The commonality of the data seems to point towards the use of coronavirus inflammatory indices (CRP, LDH, ferritin, D-dimer, and normal procalcitonin) in these patients to predict acuteness, severity of illness, and prognosis. [14] [15] [16] [17] This article is protected by copyright. All rights reserved.

In both Luo et al 14 Table 7 .

TCZ functions by inhibiting the IL-6 receptor resulting in an increased level of unbound IL-6 as was seen in our study. 18 However, our patients' average IL-6 levels initially increased through day 3 of therapy and stayed elevated until around the day of discharge. It appears that the early use of TCZ may result in a reduction of CRS, thus reducing the possibility of MV. 19 We seemed to observe this in most of the patients in this study wherein there appeared to be a reduction in the number of patients who were intubated. We find this encouraging as once they are intubated, the rates of mortality and morbidity in this population appear to be high. 10, 20 Previous studies did not have complete laboratory data documented as we did in this study. We also believe that the inflammatory indices seen in our study may prove to be helpful in the diagnosis and treatment of these patients. Issa et al 21 supports our conclusions that TCZ use is beneficial in reducing fevers, shortening hospital duration, and improving patients' respiratory and pro-inflammatory markers. 21 Additionally, Issa et al 21 reports an association between elevated IL-6 levels and severe SARS-CoV-2 cases. 21 Our study is unique, however, in that we apply this association by measuring and using IL-6 levels as a prognostic indicator. This article is protected by copyright. All rights reserved.

Although the use of corticosteroids is a conventional therapy in treating cytokine storms, their use in viral pneumonia remains controversial. 9, 11, 14 A meta-analysis demonstrates that corticosteroid monotherapy may reduce hospitalization time but increases the risk of hyperglycemia and mortality. 11 However, we found it to be effective in treating CRS after the use of TCZ. 11 The 72-hour steroid therapy was chosen to be hopefully an additive to the IL-6 inhibitor in prolonging the suppression of CRS and decreasing long-term steroid effects. 12, 14 Some of the limitations of this study include 1) cultural diversity of the patients 2) lack of a control group 3) lack of long-term follow up over 4 weeks 4) the addition of steroids could have possibly enhanced the robust effects of the IL-6 inhibitor, creating a bias as to which drug was effective.

This study was designed as a pilot study to examine the clinical outcomes in patients with SARS-CoV-2 infection in early respiratory failure using TCZ. Although not definitive, it appears to show that the early use of this drug, when used in patients requiring > 3 L O2, reduced the cytokine storm and inflammatory response in the majority of patients. This reduction in CRS appeared to decrease the need to mechanically ventilate these patients, thus reducing the mortality and morbidity. In addition, this study suggested that the use of SARS-CoV-2 inflammatory indices such as CRP, LDH, ferritin, and D-dimer are useful when used regularly and in a structured manner. 

IRB

Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release storm (CRS)

Use of tocilizumab for COVID-19 infectioninduced cytokine release syndrome: A cautionary case report

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 (IL-6R) receptor antagonist Tocilizumab may be the key to reduce mortality

The laboratory diagnosis of COVID-19-Frequently-Asked Questions

IL-6 inhibitor: Are we already that far

Publication date unavailable. Update date unavailable

Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases

Coronavirus disease 2019 (COVID-19): a clinical update

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China

Countermeasures to COVID-19: Are immunomodulators rational treatment options-a critical review of the evidence

Tocilizumab treatment in COVID-19: A single center experience

Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection

Tocilizumab, an anti-IL6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab

Why tocilizumab could be an effective treatment for severe COVID-19?

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Feasibility of Tocilizumab in ICU patients with COVID-19

The authors declare no conflicts of interest or financial conflict. 32